Evercore ISI Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to Outperform
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” rating in a research report issued on Friday, Marketbeat Ratings reports. The brokerage currently has a $99.00 price objective on the stock, up from their prior price objective of $60.00. Evercore ISI’s price target suggests a […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” rating in a research report issued on Friday, Marketbeat Ratings reports. The brokerage currently has a $99.00 price objective on the stock, up from their prior price objective of $60.00. Evercore ISI’s price target suggests a […]
